Kadcyla Inventor Took on a role at $APC.v.
$APC.v was selected for a presentation at the World Molegular Imaging Congress.
This is a merit based selection and was awarded because of the positive results of their Zeglis Lab trials. More details of which will be explained to the WMIC tomorrow.
Quite interesting to see a company this small invited to a world leading medical conference to present. This is not a pay to play promo conference. This is an industry staple where blue chip biotech's are more likely to be presenting than the entry level biotechs.
I'm hearing Dr. Ravi Chari the combination of matter patent inventor for Kadcyla has taken a role with $APC because he see's an opportunity in the patent portfolio to both recessitate failed chemo/radiation drugs. But also to develop new drugs from scratch.
Not to mention this company has isolated six candidates for covid therapies. Given the variant situation who knows how many unique therapies will be needed to treat covid long term. $APC has a chance to deliver one or more of those solutions!
Have to think with programs this lit, and blue chip biotechs so cash rich. It won't be long before a company like $APC has a new shareholder, licence or a financing lead by a major biotech company.
In times like these investments like that are like outsourcing work with a cherry if you succeed. This day doesn't feel far away!